Indoco Remedies Past Earnings Performance
Past criteria checks 1/6
Indoco Remedies has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 11.6% per year. Indoco Remedies's return on equity is 2.7%, and it has net margins of 1.8%.
Key information
13.4%
Earnings growth rate
13.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.6% |
| Return on equity | 2.7% |
| Net Margin | 1.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indoco Remedies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 17,732 | 321 | 4,685 | 875 |
| 30 Jun 24 | 18,223 | 767 | 3,677 | 980 |
| 31 Mar 24 | 18,173 | 985 | 4,621 | 972 |
| 31 Dec 23 | 17,958 | 1,016 | 4,219 | 979 |
| 30 Sep 23 | 17,356 | 1,134 | 4,141 | 936 |
| 30 Jun 23 | 16,869 | 1,281 | 3,307 | 866 |
| 31 Mar 23 | 16,686 | 1,423 | 3,941 | 810 |
| 31 Dec 22 | 16,496 | 1,569 | 3,718 | 766 |
| 30 Sep 22 | 16,084 | 1,617 | 3,616 | 738 |
| 30 Jun 22 | 15,622 | 1,537 | 3,014 | 764 |
| 31 Mar 22 | 15,408 | 1,548 | 3,435 | 746 |
| 31 Dec 21 | 14,368 | 1,393 | 3,407 | 714 |
| 30 Sep 21 | 14,110 | 1,317 | 3,423 | 716 |
| 30 Jun 21 | 13,524 | 1,157 | 2,832 | 660 |
| 31 Mar 21 | 12,415 | 930 | 3,341 | 597 |
| 31 Dec 20 | 12,084 | 734 | 3,372 | 573 |
| 30 Sep 20 | 11,654 | 571 | 3,326 | 529 |
| 30 Jun 20 | 11,298 | 393 | 2,614 | 488 |
| 31 Mar 20 | 11,066 | 241 | 3,167 | 497 |
| 31 Dec 19 | 10,909 | 302 | 2,916 | 488 |
| 30 Sep 19 | 10,640 | 264 | 2,825 | 483 |
| 30 Jun 19 | 10,071 | 111 | 2,767 | 494 |
| 31 Mar 19 | 9,684 | -29 | 2,721 | 515 |
| 31 Mar 18 | 10,424 | 412 | 2,637 | 535 |
| 31 Mar 17 | 10,968 | 771 | 2,605 | 517 |
| 31 Mar 16 | 10,081 | 819 | 2,141 | 432 |
| 31 Mar 15 | 8,570 | 828 | 1,664 | 217 |
| 31 Mar 14 | 7,336 | 580 | 2,616 | 208 |
Quality Earnings: 532612 has a high level of non-cash earnings.
Growing Profit Margin: 532612's current net profit margins (1.8%) are lower than last year (6.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532612's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: 532612's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 532612 had negative earnings growth (-71.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20%).
Return on Equity
High ROE: 532612's Return on Equity (2.7%) is considered low.